Abstract
Background To reduce the coronavirus disease burden in England, along with many other countries, the Government implemented a package of non-pharmaceutical interventions (NPIs) that have also impacted other transmissible infectious diseases such as norovirus. It is unclear what future norovirus disease incidence is likely to look like upon lifting these restrictions.
Methods Here we use a mathematical model of norovirus fitted to community incidence data in England to project forward expected incidence based on contact surveys that have been collected throughout 2020-2021.
Results We report that susceptibility to norovirus infection has likely increased between March 2020 to mid-2021. Depending upon assumptions of future contact patterns incidence of norovirus that is similar to pre-pandemic levels or an increase beyond what has been previously reported is likely to occur once restrictions are lifted. Should adult contact patterns return to 80% of pre-pandemic levels the incidence of norovirus will be similar to previous years. If contact patterns return to pre-pandemic levels there is a potential for the expected annual incidence to be up to 2-fold larger than in a typical year. The age-specific incidence is similar across all ages.
Conclusions Continued national surveillance for endemic diseases such as norovirus will be essential after NPIs are lifted to allow healthcare services to adequately prepare for a potential increase in cases and hospital pressures beyond what is typically experienced.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The study is a simulation, no data were collected as part of the study
Funding Statement
This research was primarily funded by the Wellcome Trust Noropatrol [grant code203268/Z/16/Z]. Additional funding is acknowledged from Public Health England (PHE) which is an executive agency of the Department of Health and Social Care (DHSC) and National Institute for Health USA (NIAID 1R01 AI148260). CoMix is funded by the EU Horizon 2020 Research and Innovations Programme - project EpiPose (Epidemic Intelligence to Minimize COVID-19s Public Health, Societal and Economical Impact No 101003688) and by the Medical Research Council (Understanding the dynamics and drivers of the COVID-2019 epidemic using real-time outbreak analytics MC_PC 19065).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research was exempt from ethical approval because it is a simulation study, no data were collected as part of this research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The code and data used to conduct these analyses are found at https://github.com/kath-o-reilly/norovirus_NPIs. For data access to the SGSS data used in the study applicants can apply to the PHE team by emailing noroOBK@phe.gov.uk
Abbreviations
- IID
- Infectious Intestinal Disease
- NPI
- Non pharmaceutical interventions
- SGSS
- Second Generation Surveillance System